Atara Biotherapeutics (ATRA) Current Assets (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Current Assets for 14 consecutive years, with $13.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 45.38% year-over-year to $13.5 million; the trailing twelve-month figure through Jun 2026 stood at $13.5 million (down 45.38% YoY), and the FY2025 full-year result was $12.2 million, down 81.18% from the prior year.
• Current Assets advanced to $13.5 million in Q2 2026 per ATRA's latest filing, from $12.2 million in the prior quarter.
• Across five years, Current Assets topped out at $347.0 million in Q2 2022 and bottomed at $12.2 million in Q1 2026.
• Historically, Current Assets has averaged $127.2 million across 5 years, with a median of $96.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Current Assets dropped 11.56% in 2022, then tumbled 81.18% in 2025.
• Over 5 years, Current Assets stood at $295.1 million in 2022, then tumbled by 65.48% to $101.9 million in 2023, then plunged by 36.3% to $64.9 million in 2024, then sank by 81.18% to $12.2 million in 2025, then climbed by 10.79% to $13.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $13.5 million, $12.2 million, and $12.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.